D. Mildvan

发表

Tuberculosis and the acquired immunodeficiency syndrome at a New York City hospital: 1978-1985.

S. Handwerger, F. Mckinley, D. Mildvan, 1987, Chest.

Herpes zoster ophthalmicus in patients at risk for AIDS.

T. Croxson, D. Mildvan, E. Sandor, 1984, The New England journal of medicine.

Predictors and outcome of multidrug-resistant tuberculosis.

B. Kreiswirth, N. Salomon, D. Perlman, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

T. Flynn, R. Bosch, E. Adams, 2009, Vaccine.

The bone marrow in AIDS. A histologic, hematologic, and microbiologic study.

T. Croxson, D. Mildvan, A. Castella, 1985, American journal of clinical pathology.

Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992.

S. Friedman, B. Frank, S. Yancovitz, 1994, JAMA.

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).

W. El-Sadr, N. Salomon, D. Perlman, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1

M. Altfeld, M. Carrington, J. Lifson, 2009, Nature Medicine.

“Informed Altruism” and “Partner Restriction” in the Reduction of HIV Infection in Injecting Drug Users Entering Detoxification Treatment in New York City, 1990–2001

D. D. Des Jarlais, H. Hagan, S. Friedman, 2004, Journal of acquired immune deficiency syndromes.

A Complication of Campylobacterfetus Septicemia

D. Mildvan, J. Anolik, J. Winter, 2017 .

Mycotic aortic aneurysm. A complication of Campylobacter fetus septicemia.

D. Mildvan, J. Anolik, J. Winter, 1983, Archives of internal medicine.

Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U).

A. Friedman, D. Mildvan, F. Lerebours, 1987, Ophthalmology.

Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001

D. D. Des Jarlais, L. Torian, H. Hagan, 2005, AIDS.

Treatment of Community-Acquired Pneumonia in Immunocompromised Adults

Stephen Furmanek, R. Cavallazzi, J. Ramirez, 2020, Chest.

Treatment of Community-Acquired Pneumonia in Immunocompromised Adults

Stephen Furmanek, R. Cavallazzi, J. Ramirez, 2020, Chest.

Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease.

S. Zolla-Pazner, W. El-Sadr, S. Friedman, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Biological Validation of Self‐Reported AIDS Risk Reduction among New York City Intravenous Drug Users

S. Friedman, D. Mildvan, D. C. Jarlais, 1988 .

Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus.

S. Spector, D. Cederberg, J. Mills, 1987, The American journal of medicine.

The Association of Cytopenias and Weight Loss with Hepatitis C Virus Virologic Response in HIV/HCV-Coinfected Patients Treated with PEG-IFN and RBV

J. Slim, D. Mildvan, E. Korner, 2013, Journal of the International Association of Providers of AIDS Care.

Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV

G. Robbins, R. Bosch, T. Schacker, 2010, Journal of acquired immune deficiency syndromes.

Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention

H. Wolfe, N. Leonard, M. Riedel, 2015, AIDS and Behavior.

Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

H. Kessler, S. Follansbee, D. Mildvan, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictive markers of HIV-related weight loss and determination of differences between populations with weight loss stratified by opportunistic processes.

J. Currier, D. Mildvan, R. Clark, 1999, Journal of acquired immune deficiency syndromes.

Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

D. Mildvan, J. Ruhe, 2013, Infectious disease clinics of North America.

Noninvasive methods for detection of valve vegetations in infective endocarditis.

D. Mildvan, M. Berger, E. Goldberg, 1981, The American journal of cardiology.

Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study

D. Mildvan, G. Tillotson, T. Lodise, 2020, Open forum infectious diseases.

Sexual transmission of enteric protozoa and helminths in a venereal-disease-clinic population.

M. White, D. Mildvan, S. C. Phillips, 1981, The New England journal of medicine.

Intravenous drug use and the heterosexual transmission of the human immunodeficiency virus. Current trends in New York City.

D. D. Des Jarlais, W. El-Sadr, E. Wish, 1987, New York state journal of medicine.

Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers.

D. Armstrong, D. Mildvan, M. Tapper, 1984, Annals of internal medicine.

The spectrum of HIV‐1-related disease among outpatients in New York City

R. Holzman, A. Greenberg, G. Friedland, 1992, AIDS.

Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.

J. Garber, W. El-Sadr, S. Friedman, 1987, AIDS.

The syndrome of unexplained generalized lymphadenopathy in young men in New York City. Is it related to the acquired immune deficiency syndrome?

H. Falk, L. Schonberger, J. Curran, 1984, JAMA.

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.

R. Pollard, J. Graybill, D. Mildvan, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Weight loss associated with HIV seroconversion among injection-drug users.

R. Shore, D. D. des Jarlais, D. Mildvan, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Persistent, generalized lymphadenopathy among homosexual males.

B. Safai, D. Armstrong, D. Mildvan, 1982, MMWR. Morbidity and mortality weekly report.

IRON AND IRON BINDING PROTEINS IN PERSISTENT GENERALISED LYMPHADENOPATHY AND AIDS

E. Lustbader, D. Mildvan, W. London, 1984, The Lancet.

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

M A Fischl, R. Schooley, D. Richman, 1987, The New England journal of medicine.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex

D. Mildvan, S. Grossberg, I. Wilets, 1992, The Lancet.

Concentrations of Soluble CD95 and CD8 Antigens in the Plasma and Levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T Cells Are Markers for HIV-1 Infection and Clinical Status

H. Sacks, Jian-Dong Jiang, D. Mildvan, 1997, Journal of Clinical Immunology.

Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction.

J. Sninsky, S. Kwok, G. Ehrlich, 1989, Blood.

An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex.

C. Pettinelli, H. Sacks, F. Rhame, 1991, Journal of acquired immune deficiency syndromes.

Pharmacokinetic Interaction Between Nevirapine and Ethinyl Estradiol/Norethindrone When Administered Concurrently to HIV‐Infected Women

D. Mildvan, M. Lamson, A. Marshak, 2002, Journal of acquired immune deficiency syndromes.

Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

W. Blattner, Helen H. Lee, S. Weiss, 1990, The Journal of infectious diseases.

Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.

D. Perlman, D. Mildvan, T. Jodlowski, 2014, American journal of infection control.

Follow-up at 41/2 years on homosexual men with generalized lymphadenopathy.

D. Mildvan, R. Senie, U. Mathur-Wagh, 1985, The New England journal of medicine.

Intranasal transmission of hepatitis C virus: virological and clinical evidence.

M. Simm, M. Clatts, S. Tortu, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.

S. Handwerger, D. Mildvan, D. Shonekan, 1997, The Journal of antimicrobial chemotherapy.

HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Samuel R. Friedman, Don C. Des Jarlais, S. Friedman, 1989, JAMA.

Opportunistic infections and immune deficiency in homosexual men.

R. Winchester, I. Spigland, D. Mildvan, 1982, Annals of internal medicine.

Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS).

A. Friedman, W. Freeman, I. Spigland, 1983, The British journal of ophthalmology.

Pulmonary infections in the acquired immunodeficiency syndrome.

D. Mildvan, W. Talavera, 1986, Seminars in respiratory infections.

Salmonella bacteremia associated with the acquired immunodeficiency syndrome (AIDS).

R. Nadelman, S. Yancovitz, D. Mildvan, 1985, Archives of internal medicine.

Clinical features and outcome of HIV‐related cytomegalovirus pneumonia

C. Eber, N. Salomon, D. Perlman, 1997, AIDS.

Atlas of AIDS

D. Mildvan, Gerald L. Mandell, Donna Mildvan, 2001, Current Medicine Group.

Atypical mycobacteria and Kaposi's sarcoma in the same biopsy specimens.

T. Croxson, D. Mildvan, D. Ebanks, 1983, The New England journal of medicine.

INCREASED FREQUENCY OF HLA-DR5 IN LYMPHADENOPATHY STAGE OF AIDS

R. Winchester, D. Mildvan, R. Enlow, 1983, The Lancet.

LONGITUDINAL STUDY OF PERSISTENT GENERALISED LYMPHADENOPATHY IN HOMOSEXUAL MEN: RELATION TO ACQUIRED IMMUNODEFICIENCY SYNDROME

R. Winchester, H. Sacks, I. Spigland, 1984, The Lancet.

Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference

R. Schooley, J. Phair, M. Hirsch, 1993 .

Herpes zoster ophthalmicus in patients at risk for the acquired immune deficiency syndrome (AIDS).

T. Croxson, D. Mildvan, E. Sandor, 1986, American journal of ophthalmology.

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

M A Fischl, M. Hirsch, D. Richman, 1987, The New England journal of medicine.

Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings of the Anemia Prevalence Study*

D. Mildvan, G. Leitz, T. Creagh, 2007, Current medical research and opinion.

Anemia in HIV infection: clinical impact and evidence-based management strategies.

P. Volberding, D. Dieterich, M. Saag, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Abnormalities of serum amylase and lipase in HIV-positive patients

A. Argiris, D. Mildvan, U. Mathur-Wagh, 1999, American Journal of Gastroenterology.

Nested Case-Control Study of the Emergence of Tigecycline Resistance in Multidrug-Resistant Klebsiella pneumoniae

D. Perlman, D. Mildvan, T. Jodlowski, 2013, Antimicrobial Agents and Chemotherapy.

Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U).

D. Cederberg, S. Handwerger, S. Yancovitz, 1988, The British journal of ophthalmology.

Catfish spine envenomation and bacterial abscess with Proteus and Morganella: a case report

D. Mildvan, R. Goldstein, Gary Huang, 2013, Journal of Medical Case Reports.

Venereal transmission of enteric pathogens in male homosexuals. Two case reports.

D. Mildvan, A. Gelb, D. William, 1977, JAMA.

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

J. Kahn, D. Shepp, D. Mildvan, 2001, The Journal of antimicrobial chemotherapy.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus.

D. Mildvan, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex

Robert T. Schooley, R. Schooley, P. Volberding, 1989 .

Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine

R. Haubrich, D. Richman, H. Burger, 1998, Antiviral Therapy.

Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group.

P. Volberding, B. Cheson, J. Groopman, 1987, JAMA.

Prevalence of human herpesvirus 8 DNA sequences in several patient populations

S. Remick, D. Mildvan, B. Poiesz, 1996, Journal of clinical microbiology.

Entamoeba histolytica antigen-specific induction of human immunodeficiency virus replication

D. Mildvan, B. Poiesz, H. Mathews, 1988, Journal of clinical microbiology.

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen

M. Lederman, D. Kuritzkes, Heather A Baird, 2005, AIDS research and therapy.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients

J. Eron, A. Landay, D. Mildvan, 2004, HIV medicine.

Primary cerebral lymphoma in acquired immunodeficiency syndrome (AIDS)--CT manifestations.

N. Leeds, D. Mildvan, D. Orron, 1989, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

Some serum protein and cellular constituents of inflammatory lesions. Collection of exudates in a chamber adhered over skin wounds of rabbits.

W. H. Sheldon, D. Mildvan, J. Allen, 1967, The Johns Hopkins medical journal.

Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci

S. Handwerger, D. Mildvan, D. Shonekan, 1992, Antimicrobial Agents and Chemotherapy.

A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City

D. Mildvan, M. Marmor, D. Benezra, 1988, Science.

Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.

J. Fahey, D. Mildvan, S. Grossberg, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An approach to the validation of markers for use in AIDS clinical trials.

V. De Gruttola, V. Gruttola, A. Landay, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City.

W. El-Sadr, N. Dubin, S. Friedman, 1987, AIDS.

The spectrum and causes of liver diseases in narcotic addicts.

D. Mildvan, R. Stenger, A. Gelb, 1977, The American journal of gastroenterology.

Sexual Transmission of Enteric Protozoa and Helminths in a Venereal-Disease-Clinic Population

M. White, D. Mildvan, S. C. Phillips, 1982 .

Isoenzyme analysis of Entamoeba histolytica isolated from homosexual men.

G. Healy, D. Mildvan, D. Moss, 1986, The Journal of infectious diseases.

14C-Glucose Oxidation in Whole Blood: a Clinical Assay for Phagocyte Dysfunction

S. Hirschman, G. Keusch, S. Douglas, 1972, Infection and immunity.

Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.

D. Haas, A. Landay, D. Mildvan, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection

D. Mildvan, 2001 .

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Minorities Remain Underrepresented in HIV/AIDS Research Despite Access to Clinical Trials

S. Cohn, Kimberly Smith, D. Mildvan, 2014, HIV clinical trials.

Role of Bronchoalveolar Lavage in the Diagnosis of Pneumonia

D. Cederberg, J. Mills, D. Mildvan, 2017 .

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.

P Bacchetti, R. Chaisson, H. Sacks, 1991, BMJ.

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.

R. Schooley, D. Richman, P. Volberding, 1989, JAMA.

HIV and aging

D. Mildvan, Sanjiv S. Shah, 2006, Current infectious disease reports.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

J. Lawrence, A. Zolopa, R. Bosch, 2006, The Journal of infectious diseases.

A clinical definition of HIV-associated disease

D. Mildvan, S. Solomon, 1987 .

INFECTION OF CHIMPANZEES BY HUMAN T-LYMPHOTROPIC RETROVIRUSES IN BRAIN AND OTHER TISSUES FROM AIDS PATIENTS

L. Montagnier, L. Epstein, D. Gajdusek, 1985, The Lancet.

Kikuchi-Fujimoto disease and acute appendicitis

D. Mildvan, M. Nigo, Nirav Patel, 2014, BMJ Case Reports.

Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.

D. Kuritzkes, D. Haas, R. Bosch, 2004, The Journal of infectious diseases.

Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

M. Lederman, R. Gelman, K. Squires, 2004, Journal of acquired immune deficiency syndromes.

Virus-associated colitis in homosexual men: two case reports.

I. Spigland, D. Mildvan, H. Ehya, 1983, The American journal of gastroenterology.

HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services.

Don C Des Jarlais, Samuel R Friedman, D. D. Des Jarlais, 2005, American journal of public health.

Bone invasion in secondary syphilis: case reports.

D. Mildvan, M. Gurguí, J. Barrio, 1988, Genitourinary medicine.

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

M. Lederman, D. Kuritzkes, H. Kessler, 2003, The Journal of infectious diseases.

HIV‐1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

J Weber, S. Yancovitz, D. Mildvan, 1989, JAMA.

HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited Cohorts

L. Sanfilippo, H. Wolfe, N. Leonard, 2014, Front. Public Health.

Changes in weight and lean body mass during highly active antiretroviral therapy.

C. Shikuma, K. Mulligan, D. Mildvan, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study.

M. Fischl, W. King, J. Mitty, 2007, AIDS patient care and STDs.

The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and Hispanics.

N. Leonard, M. Riedel, D. Mildvan, 2011, American journal of public health.

TheEffectofPeer-DrivenInterventiononRatesofScreening forAIDSClinicalTrialsAmongAfricanAmericansandHispanics

N. Leonard, M. Riedel, D. Mildvan, 2011 .

An Exploratory Behavioral Intervention Trial to Improve Rates of Screening for AIDS Clinical Trials Among Racial/Ethnic Minority and Female Persons Living with HIV/AIDS

N. Leonard, G. Arredondo, M. Riedel, 2010, AIDS and Behavior.

Possible pathogenic implications of right-sided polymicrobial endocarditis in a heroin abuser

D. Mildvan, J. Ollé-Goig, 1986, European Journal of Clinical Microbiology.

ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial

N. Leonard, M. Riedel, D. Mildvan, 2014, AIDS and Behavior.

Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS.

F. Brun-Vézinet, J. Chermann, F. Barré-Sinoussi, 1985, JAMA.

Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease

Douglas D. Richman, Harold A. Kessler, Richard D. Moore, 1991 .

Impact of Results of Methicillin-Resistant Staphylococcus, aureus Surveillance Culture of Nasal Specimens on Subsequent Antibiotic Prescribing Patterns

B. Kreiswirth, D. Perlman, D. Mildvan, 2010, Infection Control & Hospital Epidemiology.

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study

D. Podzamczer, H. Valdez, M. Leal, 2013, Journal of acquired immune deficiency syndromes.

Description of an efficacious behavioral peer-driven intervention to reduce racial/ethnic disparities in AIDS clinical trials.

N. Leonard, G. Arredondo, M. Riedel, 2013, Health education research.

Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.

D. Mildvan, M. Lamson, A. Marshak, 2002 .

Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor α, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2

M. Lederman, R. Gelman, R. Walker, 2002 .

Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.

C. Flexner, A. Hsu, J. Aberg, 2001 .

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

V. Johnson, M. Saag, I. Frank, 2006, The Journal of infectious diseases.

Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.

M. Lederman, R. Gelman, R. Walker, 2002, AIDS research and human retroviruses.

Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.

M. Lederman, D. Mildvan, R. Coombs, 2002 .

Increasing and Supporting the Participation of Persons of Color Living with HIV/AIDS in AIDS Clinical Trials

N. Leonard, M. Riedel, D. Mildvan, 2010, Current HIV/AIDS reports.

Lower CD4+ T Lymphocyte Nadirs May Indicate Limited Immune Reconstitution in HIV-1 Infected Individuals on Potent Antiretroviral Therapy: Analysis of Immunophenotypic Marker Results of AACTG 5067

S. Evans, M. Jacobson, D. Mildvan, 2005, Journal of Clinical Immunology.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

C. Flexner, R. Gross, J. Aberg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068

C. Pettinelli, H. Sacks, M. Fischl, 1996 .

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.

C. Pettinelli, H. Sacks, M. Fischl, 1996, Antiviral therapy.

Comparative InVitro Activities ofTeicoplanin, Daptomycin, Ramoplanin, Vancomycin, andPD127,391 against Blood Isolates ofGram-Positive Cocci

D. Mildvan, D. Shonekan, Sandrahandwerger, 1992 .

Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds

M. Finkelstein, N. Leonard, D. Mildvan, 2006, AIDS care.

Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401

C. Flexner, A. Hsu, J. Aberg, 2001, Journal of acquired immune deficiency syndromes.

HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

M. Kreek, S. Yancovitz, D. Mildvan, 1989 .

Placebo‐Controlled Trial of Cyclosporin‐A in HIV‐1 Disease: Implications for Solid Organ Transplantation

M. Lederman, D. Mildvan, R. Coombs, 2002, Journal of acquired immune deficiency syndromes.

Predictors of Screening for AIDS Clinical Trials Among African-Americans and Latino/Hispanics Enrolled in an Efficacious Peer-Driven Intervention: Uncovering Socio-Demographic, Health, and Substance Use-Related Factors That Promote or Impede Screening

N. Leonard, M. Riedel, D. Mildvan, 2013, AIDS and Behavior.

Prognostic significance of quantitative levels of HIV p24 binding capacity in HIV infection.

S. Handwerger, S. Yancovitz, T. Croxson, 1990, AIDS research and human retroviruses.

by polymerase chain reaction infection among high-risk individuals: type-specific identification of HTLVs Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II

J. Sninsky, S. Kwok, G. Ehrlich, 2011 .

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

D. Katzenstein, K. Marder, K. Tashima, 2007, Neurology.

The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.

D. Richman, F. Vaida, S. Little, 2010, The Journal of infectious diseases.

HIV and aging

D. Mildvan, Sanjiv S. Shah, 2006, Current infectious disease reports.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.